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More than 330,000 cases of colorectal cancer (CRC) are
registered each year in Europe. 1 Most patients (70%)
present with stage I−III disease and are candidates for
immediate surgery. Adjuvant chemotherapy extends the
likelihood of cure to a further 10−20% of patients with
stage III disease.
Liver metastases occur in approximately 45% of all
CRC patients (15−25% as synchronous and 15−20% as
metachronous metastases) and account for a substantial
proportion of CRC-related deaths. 2 The combined bene-
ﬁts of improved palliative chemotherapy (with the rou-
tine inclusion of biologic agents to standard regimens)
and surgical resection of liver-limited disease (± lung)
have improved outcomes for these patients. Today the
median survival for all patients with metastatic CRC
is approximately 24 months 3 and nearly one-third of
patients with unresectable CRC liver metastases are
expected to survive beyond 36 months. 3
An estimated 20−30% of patients with advanced CRC
(without extrahepatic disease, but including those with
evidence of bilateral spread in the liver and those
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responsive to neoadjuvant chemotherapy) are now being
considered as candidates for hepatectomy. 4,5 Multiple
resections can be performed, provided there is sufﬁcient
remnant liver (>30%). Among carefully selected patients,
5-year survival is 40−50%, and approximately half of
these (20%) are alive at 10 years and considered cured. 6,7
There is a great debate about how to deﬁne resectable,
potentially resectable and unresectable liver metastases
as the strategy for clinical management in each group is
very different.
ESMO Clinical Practice Guidelines for the treatment
of advanced CRC recommend that for patients who are
ineligible for aggressive initial chemotherapy, physicians
consider a conservative approach, combining 5-FU
with capecitabine and bevacizumab. 8 When aggressive
chemotherapy is indicated (for example in rapidly
progressing disease or when secondary surgery may be
possible), then the efﬁciency of initial lines of chemo-
therapy can be improved using aggressive chemotherapy
regimens and adapting treatment according to the
patient and tumour (KRAS) status (Fig. 1). 8
Non-surgical locoregional treatments have been less
extensively explored in the management of patients
with liver-limited disease. Nevertheless, it is recognised
that these treatments may play an important role in
maintaining or improving the local control of CRC
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Fig. 1 – First-line strategy for metastatic colorectal
cancer. WT, wild type; MUT, mutant; Cap., capecitabine;
bev., bevacizumab; doublet, doublet of cytotoxics. From
Van Cutsem E et al. 8 Ann Oncol 2010;21:v93−7. Reproduced
with permission from Oxford University Press on behalf of
the European Society for Medical Oncology.
liver metastases and thereby extending the life of
patients. Locoregional treatment can be used in three
settings: consolidating the response to chemotherapy,
treating disease progression following liver resection
and in the salvage setting for patients who have
failed multiple lines of chemotherapy. A number of
locoregional treatments have been developed, including
intra-arterial chemotherapy (in the 1960s) and more
recently chemoembolisation with drug-eluting beads
(irinotecan, doxorubicin) and selective internal radiation
therapy (SIRT), also known as radioembolisation. 9−13
For disease restricted to a few small nodules in
the liver, ablation and external beam radiotherapy
have also shown some promising results in small
case series. 14,15 However, none of these treatments are
currently supported by large randomised clinical trials
and so further evaluation is required.
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